|  |  | Sensitivity | Specificity | Positive predictive value | Negative predictive value | Area under the curve | Univariate logistic regression | Multivariate logistic regressionc | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
 |  | N total | Se | (95% CI) | Sp | (95% CI) | PPV | (95% CI) | NPV | (95% CI) | AUC | (95% CI) | OR | (95% CI) | OR | (95% CI) |
Functional decline a | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
aCGA | Cancer patients | 115 | 71% | (59% - 82%) | 33% | (20% - 48%) | 59% | (47% - 70%) | 46% | (29% - 63%) | 0.52 | (0.43 - 0.61) | 1.20 | (0.54 - 2.67) | 0.61 | (0.23 - 1.64) |
 | Persons without cancer | 187 | 67% | (55% - 78%) | 52% | (43% - 62%) | 49% | (39% - 59%) | 70% | (59% - 80%) | 0.60 | (0.53 - 0.67) | 2.23 | (1.22 - 4.09) | 1.87 | (0.93 - 3.78) |
G8 | Cancer patients | 115 | 64% | (51% - 75%) | 37% | (23% - 52%) | 58% | (45% - 69%) | 43% | (28% - 59%) | 0.50 | (0.41 - 0.59) | 1.02 | (0.47 - 2.19) | 0.67 | (0.28 - 1.65) |
 | Persons without cancer | 187 | 65% | (53% - 75%) | 57% | (47% - 66%) | 51% | (40% - 61%) | 70% | (59% - 79%) | 0.61 | (0.54 - 0.68) | 2.38 | (1.31 - 4.35) | 1.80 | (0.90 - 3.60) |
GFI | Cancer patients | 67 | 54% | (37% - 71%) | 59% | (41% - 76%) | 59% | (41% - 76%) | 54% | (37% - 71%) | 0.57 | (0.45 - 0.69) | 1.74 | (0.66 - 4.58) | 1.23 | (0.35 - 4.35) |
 | Persons without cancer | 187 | 58% | (46% - 69%) | 63% | (53% - 72%) | 52% | (41% - 63%) | 69% | (59% - 78%) | 0.61 | (0.53 - 0.68) | 2.35 | (1.29 - 4.26) | 1.83 | (0.92 - 3.65) |
VES-13 | Cancer patients | 67 | 57% | (39% - 74%) | 66% | (47% - 81%) | 65% | (45% - 81%) | 58% | (41% - 75%) | 0.61 | (0.50 - 0.73) | 2.55 | (0.95 - 6.85) | 2.58 | (0.59 - 11.22) |
 | Persons without cancer | 187 | 62% | (50% - 73%) | 66% | (56% - 75%) | 55% | (44% - 66%) | 72% | (62% - 80%) | 0.64 | (0.57 - 0.71) | 3.11 | (1.70 - 5.71) | 2.83 | (1.35 - 5.95) |
Decline in Qol b | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
aCGA | Cancer patients | 67 | 47% | (21% - 73%) | 37% | (24% - 51%) | 18% | (7% - 33%) | 70% | (50% - 86%) | 0.42 | (0.27 - 0.56) | 0.50 | (0.16 - 1.61) | 0.44 | (0.10 - 1.91) |
 | Persons without cancer | 187 | 56% | (41% - 70%) | 45% | (36% - 53%) | 27% | (19% - 37%) | 74% | (63% - 83%) | 0.50 | (0.42 - 0.58) | 1.02 | (0.53 - 1.96) | 1.14 | (0.55 - 2.39) |
G8 | Cancer patients | 67 | 67% | (38% - 88%) | 39% | (25% - 53%) | 24% | (12% - 40%) | 80% | (59% - 93%) | 0.53 | (0.39 - 0.67) | 1.25 | (0.37 - 4.19) | 1.47 | (0.36 - 6.05) |
 | Persons without cancer | 187 | 40% | (26% - 55%) | 44% | (35% - 53%) | 21% | (13% - 30%) | 67% | (56% - 76%) | 0.42 | (0.34 - 0.50) | 0.52 | (0.27 - 1.00) | 0.48 | (0.22 - 1.03) |
GFI | Cancer patients | 67 | 40% | (16% - 68%) | 50% | (36% - 64%) | 19% | (7% - 36%) | 74% | (57% - 88%) | 0.45 | (0.30 - 0.60) | 0.67 | (0.21 - 2.14) | 0.50 | (0.11 - 2.20) |
 | Persons without cancer | 187 | 42% | (28% - 57%) | 53% | (45% - 62%) | 25% | (16% - 35%) | 72% | (62% - 80%) | 0.48 | (0.40 - 0.56) | 0.83 | (0.43 - 1.59) | 0.89 | (0.42 - 1.88) |
VES-13 | Cancer patients | 67 | 47% | (21% - 73%) | 54% | (40% - 68%) | 23% | (10% - 41%) | 78% | (61% - 90%) | 0.50 | (0.36 - 0.65) | 1.02 | (0.32 - 3.23) | 0.53 | (0.10 - 2.83) |
 | Persons without cancer | 187 | 42% | (28% - 57%) | 53% | (45% - 62%) | 25% | (16% - 35%) | 72% | (62% - 80%) | 0.48 | (0.40 - 0.56) | 0.83 | (0.43 - 1.59) | 0.88 | (0.40 - 1.92) |